2023-11-26 19:01:02
LONDON/LEVERKUSEN (dpa-AFX) – Bayer boss Bill Anderson attributes the pharmaceutical division’s thin product pipeline, following the abrupt halt of a major study, to underinvestment in the past. “We had a few years of underinvestment until around 2018,” said the boss of the Dax group in an interview with the “Financial Times” (“FT”/Sunday). During this period, Bayer did not research new molecules and pursue truly important goals. The result is that the pipeline of widely developed drugs is thin compared to the patents that will expire in the coming years. He cannot correct what was not done eight or ten years ago.
At the start of last week, the sudden interruption of a major study on the anticoagulant Asundexian shocked the group’s investors, who caused the stock to fall by 18 percent in one day. The Asundexian was seen as Leverkusen’s blockbuster hope, with expected peak sales of over five billion euros per year. This will probably not be the case, at least in the important indication of treating patients suffering from atrial fibrillation and at risk of stroke, because Asundexian was unable to outperform the standard treatment in the study. interrupted.
Anderson believes, however, that the group’s research and development is on the right track following a readjustment of strategy five years ago. According to him, the new development strategy will allow the group to overcome current difficulties over time. “This is an activity with life cycles of ten to fifteen years,” said the manager. “Two of the companies that had the lowest research and development spending a decade ago were Eli Lilly and Novo Nordisk,” he said. Both are currently enjoying great success with their diabetes and weight loss medications. “These are two of the most valuable pharmaceutical companies in the world today,” Anderson said.
1701037139
#boss #Bayer #investment #pharmaceutical #research #November #p.m
